Pulse Biosciences (PLSE) Q2 2026 Earnings Call Transcript
Pulse Biosciences (PLSE) reported Q2 2026 revenue of $434,000 and GAAP net loss of $24.7 million. Cash and equivalents rose to $101.6 million by June 30, 2026 after $57.5 million in ATM proceeds. NANOPULSE-AF enrollment exceeded halfway with early October completion target; CE Mark for the catheter expected in 2H 2026.
How this was made
The 30-second read
Why it matters
The most tradable elements are the updated, time-bound clinical milestones (pivotal enrollment ahead of schedule, expanded eligibility, CE Mark submission window) and the capital actions (ATM proceeds and new facility) that affect runway and perceived execution risk.
Market read
Traders can reassess probability-weighted timelines for regulatory filings and endpoint execution, while also monitoring dilution/financing optics from the ATM and warrant proceeds.
What to watch
The transcript emphasizes enrollment and feasibility metrics, but does not quantify commercial adoption beyond early Vybrance sequential growth; investors may discount clinical progress if reimbursement, adoption, or endpoint readouts lag.
Background
Pulse Biosciences is advancing nsPFA technology across cardiac catheter (NANOPULSE-AF) and surgical clamp (NANOCLAMP-AF) programs, while commercializing its Vybrance system for soft tissue ablation.
Ticker impact
Pulse Biosciences reported Q2 results and disclosed accelerated NANOPULSE-AF enrollment, expanded pivotal size, and updated CE Mark timing for its cardiac catheter.
Bias modestly positive over days to weeks if investors view the accelerated enrollment and expanded eligibility as de-risking the pivotal path.
The call provides multiple concrete, time-bound catalysts (enrollment ahead of schedule, protocol amendment, CE Mark submission window) plus balance-sheet actions (ATM proceeds, new facility). However, it is still a transcript and does not include explicit forward guidance beyond expense range, limiting precision on valuation impact.
Market effects
Reinforces investor appetite for pulsed field ablation platforms and may raise expectations for electrophysiology device timelines and trial execution benchmarks.
European feasibility outcomes (freedom from AF and SAE rate) support the credibility of CE Mark pathway for EU commercialization.
If CE Mark timing holds, it can shift competitive expectations for non-thermal AF ablation technologies across major device markets.
Counterpoint
Accelerated enrollment and protocol expansion can also increase operational complexity and may not translate into superior efficacy or safety at final endpoints.
Key entities
- companyPulse Biosciences, Inc.
Subject of the earnings call transcript, providing Q2 financials, clinical enrollment updates, and financing details.
- clinical_programNANOPULSE-AF
U.S. pivotal study for the nPulse cardiac catheter system; enrollment exceeded halfway and completion target moved earlier.
- productVybrance system
Commercial soft tissue ablation system; Q2 revenue disclosed as disposable sales.
- partnerClayman Thyroid Center
Named partnership to support Vybrance registry data generation for benign thyroid nodules.
